OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacokinetics and Pharmacodynamics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	40
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	34
Learning pharmacometric covariate model structures with symbolic regression networks	32
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	29
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	29
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	25
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	23
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	19
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	18
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	18
Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis	17
ADPO: automatic-differentiation-assisted parametric optimization	16
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	16
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	16
Imputation of missing clock times – application to procalcitonin concentration time course after birth	15
Informatics for toxicokinetics	15
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	15
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	15
Current practices for QSP model assessment: an IQ consortium survey	15
Training the next generation of pharmacometric modelers: a multisector perspective	14
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	13
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	12
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	12
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	12
External validation of population pharmacokinetic models of adalimumab in adult patients with inflammatory bowel disease: towards model-informed precision dosing	11

Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	11
Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on phase I data	11
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	10
Development of a novel rabeprazole modified release formulation to reduce the dosing frequency: A trial and triumph with physiologically based biopharmaceutics modeling	10
Uncertainty undermines the validity of antimicrobial pharmacodynamics	9
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	9
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	9
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	9
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	9
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	9
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	9
Scoping review of the role of pharmacometrics in model-informed drug development	8
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	8
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	8
Thanks to our Reviewers of 2022!	8
Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities	8
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	8
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	8
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	7
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model	7
QSP model for AAV-mediated antibody delivery in rat brain	7
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	7
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	7
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	7
APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer’s Disease: A mixed-effects disease progression model	7
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	7
An automated pipeline to generate initial estimates for population Pharmacokinetic base models	7
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	7
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	6
A QSP PDE model of ADC transport and kinetics in a growing or shrinking tumor	6
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	6
JPKPD October Special Issue - Commentary	6
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	6
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	6
Computing optimal drug dosing with OptiDose: implementation in NONMEM	6
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	6
A physics-informed neural network approach for estimating population-level pharmacokinetic parameters from aggregated concentration data	6
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment	5
On the existence conditions of interaction indices in response surface models	5
How drug onset rate and duration of action affect drug forgiveness	5
Personalized prophylactic therapy optimization in hemophilia A using a hybrid PK-PD-TTE model and deep RL	5
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria	5
Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases	5
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin	5
An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy	5
Identification and characterization of virtual sub-populations through phenotype-guided filtering. The challenging case of nonidentifiable models in the context of therapeutic evaluation	5
External control arms for rare diseases: building a body of supporting evidence	5
In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science	5
Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?	5
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	5

Generation and application of avatars in pharmacometric modelling	5
Comparing heavy-tailed residual error models for outlier handling in population PK modeling	5
Special issue: Model-informed drug development in rare diseases: connecting the dots in an information rich ecosystem	5
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies	5
A note on phase I interleaved versus parallel group ascending dose designs for concentration-QTc analyses	5
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models	5
Utility of a physiologically-based pharmacokinetic model for investigating time-dependent variability in the fetal-to-maternal plasma concentration ratio of digoxin	5
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations	5
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	4
Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases	4
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel	4
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approach	4
Computing optimal drug dosing regarding efficacy and safety: the enhanced OptiDose method in NONMEM	4
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model	4
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies	4
Development of a population pharmacokinetics model and an R-Shiny simulation platform for moxifloxacin pharmacokinetics in non-human primates	4
An industry perspective on current QSP trends in drug development	4
Aggregate data modelling: A fast implementation for fitting pharmacometrics models to summary-level data in R	4
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma	4
Strategies for pediatric dose derivation from population pharmacokinetic models	3
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach	3
Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications	3
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics	3
Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling	3
Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial	3
The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)	3
Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease)	3
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective	3
Construction of a translational whole-body physiologically based pharmacokinetic model to investigate the biodistribution of lipid nanoparticle-based mRNA therapeutics for intracellular protein target	3
Correction: External control arms for rare diseases: building a body of supporting evidence	3
International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairs	3
A structure-preserving hybrid learning framework for compartmental pharmacokinetic models	3
Towards a comprehensive assessment of QSP models: what would it take?	3
Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations	3
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	3
Tracer kinetic modeling of a 14 kDa anti-CD8 PET tracer (2C8v144) for in vivo estimation of CD8 expression in tissue and blood, binding affinity, and total body receptor occupancy	2
A hybrid PKPD agent-based model of the tumour immune interaction: effects of anti-cancer combination therapy	2
Advancing drug development with “Fit-for-Purpose” modeling informed approaches	2
A review of the physiological effects of microgravity and innovative formulation for space travelers	2
Physiologically-based pharmacokinetic model for predicting drug-drug interactions perpetrated by posaconazole in healthy subjects with normal weight and obesity: Concomitant use and washout	2
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	2
Dos and don’ts for concentration - QTc analysis as primary analysis for assay sensitivity assessment	2
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins	2
Optimizing Subcutaneous Antibody Dosing Regimens Through Operating Space Maps: rHuPH20 Case Study	2
Fourteenth American Conference on Pharmacometrics (ACoP14) – Innovation and Diversity: Redefining Pharmacometrics	2
Correction: Tracer kinetic modeling of a 14 kDa anti-CD8 PET tracer (2C8v144) for in vivo estimation of CD8 expression in tissue and blood, binding affinity, and total body receptor occupancy	2
Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC	2
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations	2
Concentration response analyses for QT data with several active compounds	2
Leveraging large language models to compare perspectives on integrating QSP and AI/ML	2
A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization	2
The evolution of nonlinear mixed effects modeling in pharmacometrics: toward AI-based variational autoencoders	2
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases	2
Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach	2
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)	2
Ehrlich occupancy time: beyond $$k_\textrm{off}$$ to a complete residence time framework	2
Changes in Associate Editors at the Journal of Pharmacokinetics and Pharmacodynamics	2
Pharmacometrics education for all by overcoming language barriers to enhance global collaboration	2